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Abstract
With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few
cells, cancer stem or tumor-initiating cells (TICs) are a severe limitation for the treatment of cancer by conventional
therapies. Here, we explored whether human T cells that are redirected via an EpCAM/CD3-bispecific antibody called MT110
can lyse colorectal TICs and prevent tumor growth from TICs. MT110 recognizes EpCAM, a cell adhesion molecule expressed
on TICs from diverse human carcinoma, which was recently shown to promote tumor growth through engagement of
elements of the wnt pathway. MT110 was highly potent in mediating complete redirected lysis of KRAS-, PI3 kinase- and
BRAF-mutated colorectal TICs, as demonstrated in a soft agar assay. In immunodeficient mice, MT110 prevented growth of
tumors from a 5,000-fold excess of a minimally tumorigenic TIC dose. T cells engaged by MT110 may provide a potent
therapeutic means to eradicate TICs and bulk tumor cells derived thereof.
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Introduction
While mortalities of heart disease, stroke and infectious diseases
(flu and pneumonia) have declined over the past 55 years by 64, 74
and 58%, overall cancer mortality did only decline by 5%
(National Center for Health Statistics). One reason may be the
resistance of so called cancer stem or tumor-initiating cells (TICs)
to standard cancer therapies. This highly tumorigenic subpopu-
lation of cancer cells is difficult to detect and resistant to many
chemotherapeutic approaches due to overexpression of detoxifying
enzymes and multidrug resistance pumps, preference for hypoxic
niches and low proliferation rate. The significance of TICs for
cancer therapy and biology is therefore under intense research [1–
4]. Should the concept of TICs hold up, novel therapies aiming at
their elimination may treat cancer with improved outcome, if not
with a curative effect.
TICs have now been identified and characterized in numerous
human malignancies. Several laboratories have isolated TICs, e.g.,
from colorectal and pancreatic tumors, by using antibodies specific
for epithelial cell adhesion molecule (EpCAM; also called ESA)
[5,6]. Furthermore, the expression of EpCAM and CD44 was
shown to track with the tumorigenic phenotype of such cells [5,7–
10]. EpCAM is frequently expressed at high levels on primary
tumors and metastases of most human adenocarcinoma [11,12].
In several human malignancies, including breast, ovarian,
ampullary pancreas, gall bladder and liver cancers, EpCAM
overexpression correlates with a poor survival prognosis of patients
[13–17]. EpCAM has recently been described as a cancer stem cell
marker expressed together with CD44, CD133, and CD166 [18–
20].
One reason why TICs and their progeny may express EpCAM
is that the adhesion molecule can be activated by regulated intra-
membrane proteolysis allowing it to function as signaling protein
and proto-oncogene [21,22]. The released intracellular domain of
EpCAM, called EpICD, has been shown to form a nuclear
complex composed of FHL-2, b-catenin and transcription factor
TCF/LEF, which is involved in expression of c-myc and cyclin
genes. Overexpression of full-length EpCAM or EpICD in
quiescent cells elicits tumor formation. EpCAM has been selected
as target for many antibody- and vaccine-based therapeutic
approaches of which several are in clinical development [11,23]. A
trifunctional anti-EpCAM antibody has recently obtained market
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embryonic stem cells express EpCAM [24–26], but there is
evidence to suggest that EpCAM on normal epithelial tissues is
largely sequestered while it is accessible on the surface of cancer
cells [27,28].
MT110 is a T cell-engaging antibody construct of the BiTE
class i.e. bispecific T cell engager with dual specificity for EpCAM
and CD3 [29]. The principle of BiTE antibodies has been
reviewed in detail [30–33]. BiTE antibodies enable formation of a
cytolytic synapse between any cytotoxic T cell and a target cell
binding the BiTE antibody. This will fully activate T cells for
redirected lysis involving production of granzyme B, proliferation,
and adoption of a serial lysis mode [34–36]. MT110 and related
EpCAM-specific BiTE antibodies showed high anti-tumor activity
in diverse animal models [29,37–39]. A CD19/CD3-bispecific
BiTE antibody called blinatumomab showed high anti-tumor
activity in relapsed non-Hodgkin’s lymphoma patients [40],
providing clinical proof of concept for the therapeutic principle
of BiTE antibodies. MT110 is currently tested in a dose-escalating
phase 1 clinical trial in patients with lung or gastrointestinal
cancers for safety and initial signs of activity. Indicative of a
therapeutic window, studies in mice using a BiTE binding to
murine EpCAM and murine CD3 demonstrated anti-tumor
activity in the absence of damage to EpCAM-expressing normal
epithelia [37,41,42] .
Here we asked whether T cells engaged by BiTE antibody
MT110 are a means for complete elimination of EpCAM-
expressing TICs under cell culture conditions, and in immunode-
ficient mice. Primary colorectal TICs isolated from human
colorectal tumor sections and a subpopulation of in vivo-selected,
highly tumorigenic HT-29 colorectal cancer cells were here used
as source of TICs, and characterized for their tumorigenic
potential and other TIC-associated properties. By analysis of in
vitro cytotoxicity reactions with peripheral human T cells and
MT110 in soft agar for potentially surviving target cells, we
identified conditions allowing lysis of apparently all TICs. In mice,
low doses of MT110 prevented outgrowth of tumors from a 5,000-
fold excess of a minimally tumorigenic TIC dose, and all mice
treated with the two highest MT110 doses tested survived s.c.
inoculation of a highly tumorigenic cell bolus.
Materials and Methods
Tissue digestion and cell preparation
Human colorectal tumor sections were procured after patients’
written consent under an IRB study for research use of their
tissues. Tumor tissue (stage 4) had been collected from three
patients who had undergone chemo plus radiation therapy under
guidance of the Institutional Review Board from hospitals in the
Los Angeles area.
Tumor tissues were initially minced and then digested by
collagenase A (0.2 mg/ml) and trypsin (0.05 mg/ml) for 15
minutes at 37uC by gentle pipetting. The cell suspension was
centrifuged at 1006g for 7 minutes and the cell pellet washed with
complete growth medium (Celprogen, M36112-39PS) for three
times. The cells were reconstituted in un-differentiation medium
(Celprogen, M36112-39US) and cultured in pre-coated flasks with
a chemically defined matrix that selects for CD133-positive cells.
For the present study, primary colorectal tumor-initiating cells
(TICs) from one 40 year-old male colorectal cancer patient (stage
4) were selected because of their high degree of previous
characterization and expandability in cell culture.
Colon tumor xenografts derived from human CRC line HT-29
cells were removed from NOD/SCID mice and minced into
1m m
3 pieces. After one washing step in PBS, tumor tissues were
incubated in digestion buffer of the Cancer Cell Isolation Kit
(Panomics) for 1–2 h at 37uC with mechanical disruption every
30 min. Single cells were obtained through a 100 mm cell strainer
(BD Falcon), and were separated from hematopoietic and dead
cells by gently loading the cell suspension onto a layer of
purification buffer from the Cancer Cell Isolation Kit (Panomics).
Sedimented tumor cells were washed twice in PBS and checked for
vitality using trypan blue exclusion assay.
Lineage-positive host cells were depleted from tumor cells using
the MACS Lineage Cell Depletion Kit (Miltenyi Biotec). Anti-
mouse CD45 (eBioscience) and anti-mouse CD29 (eBioscience)
antibodies were used to test for the presence of contaminating
mouse cells.
Cell culture and animals
TICs were cultured in NS-A basal serum-free medium
(Euroclone) containing 2 mM L-glutamine, 0.6% glucose,
9.6 mg/ml putrescine, 6.3 ng/ml progesterone, 5.2 ng/ml sodium
selenite, 0.025 mg/ml insulin, 0.1 mg/ml transferrin sodium salt,
supplemented with 20 ng/ml EGF and 10 ng/ml basic FGF. HT-
29 cells were purchased from the American Type Culture
Collection and maintained in RPMI medium (Biochrom)
containing 10% fetal bovine serum (Biochrom).
NOD/SCID mice were obtained from the Jackson Laboratory
(Charles River). All experiments involving animals were performed
in accordance with the relevant guidelines for the care and use of
animals and with approval by the responsible animal welfare
authority, the Regierung von Oberbayern (Appoval ID: 55.2-1-54-
2531.2-12-09).
Genomic DNA sequencing
Genomic DNA was extracted from cells using the DNeasy
Blood and Tissue Kit (Qiagen) following manufacturer’s instruc-
tions. Exon 9 and 20 (codons 1023 and 1047) of PIK3CA, exon 2 of
KRAS and exon 15 of BRAF were amplified with primers
complementary to surrounding sequences. PCR products were
purified with the QIAquick Gel Extraction Kit (Qiagen) and
sequenced. Sequences have been deposited in GenBank (accession
number BankIt1358613 HM459602, HM459603, HM459604,
HM459605).
Magnetic bead isolation
CD44-positive cells derived from HT-29 xenograft tumors were
sorted using the Pan anti-Mouse Kit (Invitrogen) according to
manufacturer’s instructions. Briefly, cells were incubated 30 min
with magnetic beads pre-coated with anti-CD44 antibody
(Chemicon). CD44
high and CD44
low cells were seperated by a
Dynal magnet. CD44
high bead-bound cells were washed three
times with PBS plus 2% FCS and incubated with DNaseI to
release the cells from the beads via DNA linker cleavage. The flow-
through was incubated again with new CD44 antibody-coated
magnetic beads to obtain a pure CD44
low fraction.
Flow cytometry
Cells were trypsinized, washed with PBS containing 2% FCS
and stained with 5–10 mg/ml of the following antibodies for
30 min at 4uC: CD44-PE (Chemicon), CD24-APC (Immunostep),
CD44v6-FITC (Abcam), CD133/2-PE (Miltenyi), CD166-
ALEXA 647 (Serotec), ABCG2-PE (eBioscience), E-Cadherin
(SantaCruz) and EpCAM (MT110, Micromet AG). For analysis a
FACSCalibur flow cytometer (Beckton Dickinson) was used.
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Ten thousand to 20,000 TICs were incubated with unstimu-
lated human peripheral blood mononuclear cells (PBMCs) or
PBMCs depleted of CD4
+ T cells, CD56
+ NK and NKT cells (i.e.
enriched for CD8
+ T cells) [29] at an E:T ratio of 1:5-10:1 and
different antibody concentrations ranging from 0.01–200 ng/ml.
After incubation for 20–120 h, a soft-agar colony assay was
performed. To this end, supernatant and trypsinized cells were
suspended in RPMI medium containing 10% FCS and 0.4%
agarose and subsequently overlayed onto a solidified layer of
RPMI medium containing 10% FCS and 0.5% agarose. After 11–
17 days, colony forming units (CFU) with .70 mm in diameter
were counted. For photographs, CFU were stained with 0.05%
crystal violet (Sigma).
Transplantation of TICs or CFU
Cells were trypsinized, washed once with PBS, resuspended in
serum-free medium, mixed with matrigel (BD Biosciences) 3:1 and
injected s.c. into flanks of 6–8 weeks old female NOD/SCID mice
(Charles River Laboratories).
For transplantation of CFU, 1 or 10 colonies, .70 mmi n
diameter were picked with a micromanipulator (CellTram Oil,
Eppendorf). Colonies were immediately injected s.c. into NOD/
SCID mice. All animals were monitored once a week for tumor
formation. Growing tumors were measured with a caliper and
tumor volumes were calculated according to the formula: tumor
volume = [(width
2*length)/2].
Animals injected with colonies were generally sacrificed after
5–6 months and examined for lymph node metastasis. Metastases
were dissected, digested and analyzed by FACS using anti-human
CD24, CD44, EpCAM, and anti-murine CD45 antibodies.
Efficacy analysis of MT110 in TIC xenograft models
1610
6 human PBMCs isolated from heparinized fresh whole
blood of a healthy donor were mixed with 5610
5 TICs in a final
volume of 200 ml. The PBMC effector/target cell mixture (E:T of
2:1) was s.c. injected into the right flank of each NOD/SCID
mouse. At least 3 animals per group were intravenously treated
with MT110 or PBS control vehicle starting 2 h after inoculation
with the indicated doses. MT110 was administered daily for a total
of 12 days.
In the HT-29 model mixtures of 50,000 highly tumorigenic
HT-29 xenograft-derived CD44
high/CD24
high/EpCAM
high cells
and 1610
5 human PBMCs were inoculated into 5 NOD/SCID
mice per group. Mice were daily treated i.v. for 12 days with the
indicated doses of MT110 or with vehicle controls in the presence
of PBMCs.
For elimination of established tumors in NOD/SCID mice by
treatment with MT110 mixtures of 5610
6 TICs and 1610
7
human PBMCs were inoculated into 5 NOD/SCID mice per
group to allow solid tumor formation. After tumor establishment
at day 4, mice were treated i.v. for 14 days with 2.5 mg/kg of
MT110, or with vehicle control in presence of PBMCs.
Results
In vivo-selected, highly tumorigenic cells of colorectal
cancer line HT-29 can be eliminated by MT110-engaged
T cells
We selected a highly tumorigenic subpopulation of human
HT-29 colorectal cancer cells from tumors growing under the
skin of immunodeficient mice. Cells of the colorectal cancer line
HT-29 have a mutated BRAF gene (V600E) and are relatively
resistant to cytotoxicity by anti-EGFR antibody cetuximab [43].
We found that HT-29 cells also had a mutation in the
PIK3CA gene (E545A). Tumor cells isolated from subcutaneously
growing HT-29 tumors were sorted by CD44 and separated
into CD44
high/CD24
high/EpCAM
high and CD44
low/CD24
low/
EpCAM
low subgroups (Figure S1A). EpCAM expression tracked
with CD44 expression and was highest in the CD44
high/
CD24
high subpopulation. Both isolated subpopulations were
essentially free of murine cells as detected by the absence of
murine CD29 and CD45 expression (Figure S1B, Materials and
Methods S1).
Compared to CD44
low/CD24
low/EpCAM
low cells, CD44
high/
CD24
high/EpCAM
high cells had higher functional levels of
aldehyde dehydrogenase (ALDH) (Figure S1C, Materials and
Methods S1), a 30-fold higher tendency to form spheres in cell
culture, and a 20-fold higher tendency for colony formation in soft
agar (Figure S1D), and higher expression levels of stem cell
markers CD133, CD166, the CD44 splice variant v6 and the ABC
transporter G2 (Figure S2, Materials and Methods S1). While at
least 1610
5 non-selected HT-29 cells were required to form
tumors in immunodeficient mice (Table 1), minimally 10
CD44
high/CD24
high/EpCAM
high cells or 100 CD44
low/
CD24
low/EpCAM
low cells were sufficient for inducing a tumor
in mice in two independent experiments. This showed that we had
isolated highly tumorigenic subpopulations of cells from xenografts
with the fraction of CD44
high/CD24
high/EpCAM
high cells having
the most pronounced TIC phenotype.
In order to investigate the efficacy of MT110-engaged T cells in
redirected lysis of CD44
high/CD24
high/EpCAM
high HT-29 cells,
in vitro cytotoxicity reactions were performed using unstimulated
peripheral blood mononuclear cells (PBMCs) as source of T cells
at an effector to target (E:T) ratio of 10:1. Subsequently, cell
culture reactions were mixed with soft agar. This way, cancer cells
potentially surviving the BiTE reaction in the presence of T cells
can be detected with high sensitivity and quantified by formation
of colonies. The assay procedure is schematically shown in
Figure 1A. One (18 pM) or 100 ng/ml MT110 were sufficient to
completely eliminate tumorigenic HT-29 cells while 0.01 ng/ml
MT110, PBMC alone, or control BiTE antibodies solely binding
CD3 or EpCAM had no effect on the number of colonies formed
(Fig. 1B). A total of 20,000 CD44
high/CD24
high/EpCAM
high HT-
29 cells were used per cytotoxicity reaction, which under control
conditions gave between 110 and 145 visible colonies per cm
2
after 14 days (Fig. 1C). In a standard cytotoxicity assay, the
half maximal concentration for redirected lysis of HT-29
bulk, CD44
high/CD24
high/EpCAM
high and CD44
low/CD24
low/
EpCAM
low subgroups was determined at 1.9 +/2 0.6 ng/ml, 0.05
+/2 0.05 ng/ml and 1.5 +/2 0.1 ng/ml of MT110, respectively
(Figure S3A, Materials and Methods S1).
Characteristics of primary colorectal TICs
We next investigated colorectal TICs derived from tumor
sections of CRC patients. In order to verify their cancer stem cell
phenotype, TICs were analyzed by FACS staining for expression
of established surface markers [18], and by using RT-PCR for
expression of mRNAs coding for surface and intracellular marker
proteins. FACS staining showed that TICs were CD44
high/
CD24
high/EpCAM
high, and expressed CD133, CD166, the CD44
splice variant v6 and the ABC transporter G2 on their surface
(Figure S3A, Materials and Methods S1). RT-PCR analysis
verified the expression of the surface antigens at the mRNA level.
Furthermore, robust RT-PCR signals were detected for alkaline
phosphatase, CA199, nestin, notch-1, Oct-4, SSEA 3/4 and
telomerase. Genomic sequence analysis showed that primary
Kill of Tumor-Initiating Cells
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genes (E545K, E545T, and D549N, data not shown).
We found that a dose of 100 TICs was minimally required for
induction of tumors in NOD/SCID mice with a latency of 42–66
days (Table 1). Higher cell doses showed increasingly shorter
latency periods. Ten TICs were not sufficient to induce a tumor
during an observation period of 80 days. When TICs were grown
in cell culture, they had a tendency to form dense spheres of
100 mm in diameter and larger (Figure S4A). Under cell culture
conditions in the presence of 10% fetal calf serum (FCS), TICs
started to differentiate as shown by expression of E-cadherin [44]
and a morphological change to a more epithelial phenotype
(Figure S4B, Materials and Methods S1). In NOD/SCID mice,
10,000 TICs grown in TIC medium were more tumorigenic in
comparison to TICs cultured under serum containing conditions
(data not shown). The percentage of cells retaining their PKH26-
membrane label declined over time upon the change to the FCS-
containing medium assuming an increase in symmetric cell
division and loss of self-renewal capacity (Figure S4C, Materials
and Methods S1). When inoculated in mice, xenografts from TICs
after 4 weeks contained between 0.2% and 0.5% PKH-26 labeled
cells (Figure S4D, Materials and Methods S1), demonstrating
differentiation of most TICs but also self-renewal of a small subset
of TICs. The content of TICs in the xenografted tumors was
comparable to that found in tumor biopsies of patients. Lastly,
3,000 PKH-26 labeled cells isolated from TIC xenografts formed
tumors after re-inoculation in mice (data not shown).
In conclusion, expression of a specific set of marker proteins,
high tumorigenicity, differentiation in growth factor-containing
medium and within xenografts, formation of spheres, and self-
renewal capacity suggest that the colorectal TICs used in this study
behaved like bona fide tumor-initiating cells and were therefore
valuable as EpCAM-expressing TICs for testing the therapeutic
potential of BiTE antibody MT110 in vitro and in vivo.
Activity of MT110-redirected T cells against TICs in vitro
Redirected lysis of TICs by EpCAM-specific BiTE antibody
MT110 and T cells was investigated by using either PBMCs or
CD8
+ T cells isolated from PBMCs as effector cells. Ten to 20,000
TICs were used per assay, which, under control conditions, gave
raise to .200 colony forming units (CFUs) per cm
2 in soft agar
with a diameter of .70 mm after 2 weeks. We first determined the
minimal concentration of MT110 required for complete lysis of
TICs using CD8
+ T cells or PBMCs as effectors. An E:T ratio of
10:1 was used and the cytotoxicity reaction allowed for 20 h. A
very substantial decrease in CFU formation was already seen with
a concentration of 0.1 ng/ml MT110, i.e., 2 pM of the bispecific
antibody (Fig. 2A and 2B). Cytotoxicity reactions testing MT110
concentrations of 1, 10, 100 and 200 ng/ml showed no formation
of CFUs when analyzed in soft agar assays. In a standard
cytotoxicity assay, the half maximal concentration for redirected
lysis of TICs was determined at 0.41 +/2 0.25 ng/ml of MT110
(Figure S3B, Materials and Methods S1). Results were not
different if purified CD8
+ T cells (Fig. 2A and 2B, top) or PBMCs
(Fig. 2B, bottom) were tested, indicating that CD8
+ T cells made a
major contribution to redirected lysis and that other T
lymphocytes within PBMCs, such as regulatory T cells, did not
detectably influence lysis of TICs. The number of CFUs obtained
in the presence of human T cells was not affected by two control
BiTE antibodies at concentrations of 200 ng/ml that either solely
bound to CD3 on T cells or to EpCAM on TICs by using the
same single-chain antibody arms as in MT110.
In order to demonstrate that lysis of TICs was dependent on
immune cells and was similar with immune cells from different
human PBMC donors, four E:T ratios of 1:5, 1:1, 5:1 and 10:1
were tested for efficacy with PBMC from two human donors in
cytotoxicity reactions for 20 or 48 h using 10 ng/ml MT110.
PBMCs typically contain 15–20% CD8
+ T cells, indicating that
effective CD8
+ T cell to target cell ratios would be at least 5-fold
Table 1. Tumorigenicity of HT-29 colorectal cancer cell populations and primary colorectal TICs.
Cell Type Number Injected
Tumor
Incidence
Latency
[Days]
Lymph
Node
Metastasis
HT-29 Unsorted 100
1,000
10,000
100,000
1,000,000
0/2
0/2
0/2
2/2
2/2
.180
.180
.180
8
4
n.d.
HT-29 CD44
low/CD24
low/EpCAM
low 10
100
1,000
0/2
2/2
2/2
.180
33
33
n.d.
HT-29 CD44
high/CD24
high/EpCAM
high 10
100
1,000
2/2
2/2
2/2
33
33
33
n.d.
TICs 10
100
1,000
10,000
100,000
1,000,000
0/2
4/4
4/4
4/4
4/4
2/2
.80
42–66
37–78
21–30
10–21
10–21
n.d.
Soft Agar only 0/2 .100 0
Single TIC Colony 1 3/6 24–60 2/6
Mix of TIC Colonies 10 2/6 53–59 1/6
Subpopulations of human HT-29 cells were isolated from subcutaneously growing tumors of mice based on CD44 and CD24 expression levels. Tumorigenicity was
tested by subcutaneous injection of the indicated number of tumor cells or soft agar colonies derived from TICs into NOD/SCID mice.
doi:10.1371/journal.pone.0013474.t001
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partial reduction of CFUs after 20 h, redirected lysis at E:T ratios
of 5:1 and 10:1 almost completely prevented CFU formation in
soft agar (Fig. 2C). With PBMCs from donor 1 at an E:T ratio of
10:1, no detectable CFUs had formed after 17 days in soft agar.
We next analyzed the time dependence of TIC lysis. Compared
to a control BiTE solely binding CD3, 10 ng/ml of EpCAM/
CD3-bispecific BiTE antibody MT110 led to a pronounced
reduction of the number of CFUs after a 24 h-cytotoxicity
reaction at a low E:T ratio of PBMC to TICs of 1:1 (Fig. 2D).
Approximately 5 CFU/cm
2 were detected after cytotoxicity
reactions for 72 and 96 h, and none was seen if redirected lysis
was allowed for 120 h. Under control conditions, CFU numbers
steadily increased over time showing that TICs well proliferated in
the presence of PBMCs and the absence of MT110.
Under conditions where no CFUs were observed in soft agar
after 11–17 days, CFU formation in some cases was monitored for
up to 5 months. In no single case, CFUs were seen after this long
observation period. Figure S5 shows that soft agar conditions after
3 and 5 months still supported the outgrowth of colonies when
TICs were transferred into the aged agar. We therefore conclude
that under conditions where no CFU formation was observed, all
TICs had been lysed by MT110-redirected T cells in the
preceeding cytotoxicity reaction.
TICs growing in soft agar are highly tumorigenic and
form metastases
We further investigated whether CFUs formed in soft agar still
contain highly tumorigenic TICs. Single colonies (1 CFU<200–
300 cells) or mixes of 10 colonies were isolated from soft agar
plates and subcutaneously injected into NOD/SCID mice. While
soft agar alone did not cause tumors, tumor growth from single
colonies was observed in 50% of cases with a latency period of
24–60 days, and in 33% of cases after 53–59 days for mixes of
colonies (Table 1). CFUs did not only form local subcutaneous
Figure 1. Eradication of tumor-initiating CD44
high/CD24
high/EpCAM
high HT-29 colorectal cells by MT110-engaged T cells. (A) Scheme
of cytotoxicity assay with soft agar-based assay readout. (B) Photographs of soft agar plates with crystal violet-stained colonies growing from
CD44
high/CD24
high/EpCAM
high cells treated in the presence of T cells at the indicated concentrations of MT110, control BiTE antibodies at 100 ng/ml,
or T cells alone. (C) Effect of MT110 on the number of CFUs per cm
2. Bar graphs are mean values after 14 days from triplicate determinations +/2 SD.
Unstimulated PBMC were used as effector T cell source at an PBMC to HT-29 cell ratio of 10:1.
doi:10.1371/journal.pone.0013474.g001
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tumor-bearing mice were sacrificed and inspected, enlarged
lymph nodes were found in various locations (Fig. 3A). Cellular
analysis of lymph node homogenates by FACS staining revealed
that they contained cells expressing human CD24, CD44 and
E p C A M( F i g .3 B ,l e f t ) .T h es a m eh u m a nm a r k e rp r o t e i n sw e r e
Figure 2. Eradication of primary colorectal tumor-initiating cells (TICs) by MT110-engaged T cells. (A) Photographs of crystal violet-
stained colonies growing from TICs treated in the presence of T cells with the indicated concentrations of MT110, control BiTE antibodies at
200 ng/ml, or T cells alone. Unstimulated PBMCs were used as source of T cells at a PBMC to TIC ratio of 1:1. (B) MT110 dose response of redirected
lysis. Number of CFUs from TICs per cm
2 are shown. Bar graphs are mean values of colony numbers from triplicate determination +/2 SD observed
after 11 days. Unstimulated PBMCs or CD8
+ cells were used as effectors as indicated at an E:T ratio of 10:1. (C) Effect of E:T ratio and T cell donor on
redirected lysis. Number of CFUs per cm
2 of TIC cells treated with 10 ng/ml MT110 or a CD3-monospecific BiTE control antibody at the indicated E:T
ratios and incubation times are shown. Bar graphs are mean values of colony numbers from triplicate determination +/2 SD as observed after 17
days. Unstimulated PBMCs from two healthy blood donors were used as effector cells. (D) Time dependence of redirected lysis. Number of CFUs per
cm
2 from TICs treated with 10 ng/ml MT110 or a CD3-monospecific BiTE control antibody at a PBMC to TIC ratio of 1:1 are shown. Bar graphs are
mean values from a triplicate determination +/2 SD observed after 15 days.
doi:10.1371/journal.pone.0013474.g002
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right).
Activity of MT110 against TIC-derived tumors in a mouse
model
Initial experiments had shown that 100 TICs or 10 HT-29
CD44
high/CD24
high/EpCAM
high cells were sufficient to induce
tumors in NOD/SCID mice with a latency of 42–66 and 33 days,
respectively (Table 1). In order to test the in vivo-efficacy of MT110
against TICs and HT-29 CD44
high/CD24
high/EpCAM
high cells,
we established a mouse model where tumor growth is induced by a
5,000-fold higher dose of colorectal TICs as is minimally needed
for tumor initiation (Fig. 4). As shown in Figure 4A, 0.5610
6 TICs
caused tumors growing to a size of .0.6 cm
3 after 50 days, with
tumors detectable before day 20. The presence of human PBMCs
at an E:T ratio of 2:1 in subcutaneous tumors, as is needed by
MT110 for redirected lysis in immunodeficient mice, did not
significantly retard or reduce tumor growth. Doses of 50 or
500 mg/kg MT110 given intravenously for the first 12 days
completely prevented tumor formation for the entire observation
period of 232 days, and all mice survived inoculation of the high
TIC number (Fig. 4A). MT110 at 5 mg/kg also significantly
inhibited tumor outgrowth, and 50% of mice survived of which
Figure 3. Soft agar colonies from TICs implanted into NOD/SCID mice cause lymph node metastasis. (A) Representative photographs of
lymph node metastases derived from s.c. implanted TIC-derived soft agar colonies. (B) Representative FACS analysis of cells derived from an s.c. tumor
and a cervical lymph node of a NOD/SCID mouse s.c. implanted with a soft agar colony derived from TICs.
doi:10.1371/journal.pone.0013474.g003
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16 mm
3 for 71 days but eventually became free of tumor, and two
had to be sacrificed with large tumors for welfare reasons. In the
vehicle arm, all mice had to be sacrificed for welfare reasons 55
days after start of the experiment.
Similar results were obtained with the HT-29 CD44
high/
CD24
high/EpCAM
high tumor model (Fig. 4B). Doses of 500 mg/kg
MT110 i.v. for 12 days prevented tumor outgrowth in 5 out of 5
mice for the entire observation period of 180 days. At a dose of
50 mg MT110/kg per day, 4 out of 5 mice were free of tumor and
at a dose of 5 mg MT110/kg per day, 1 out of 5 mice was tumor-
free. This shows that T cells engaged by MT110 are capable of
eliminating also in animals an excessive dose of highly tumorigenic
TICs.
MT110 was also efficient in treatment of established tumors
derived from colorectal TICs (Fig. 4C). At a dose of 2.5 mg
MT110/kg given daily i.v. for 14 days, a complete remission of
tumors in 5 out of 5 mice until the end of the study at day 30 was
observed (Fig. 4C).
Discussion
We here show that cytotoxic human T cells engaged by
extremely low amounts of an EpCAM/CD3-bispecific antibody
construct, which is currently in a phase I trial, have the potential to
completely eradicate two kinds of highly tumorigenic colorectal
tumor-initiating cells. One kind was in vivo-selected CD44
high/
CD24
high/EpCAM
high HT-29 cells, the other primary TICs
isolated from the tumor of a CRC patient. The two cell types
showed all known hallmarks of TICs, including tumor growth
from very low cell numbers, sphere formation, expression of a
panel of markers and, in one case, of ALDH activity. Both TIC
cell types had mutations in either BRAF or KRAS and both in
PIK3CA genes that may render patients insensitive to treatment
Figure 4. Cure of NOD/SCID mice receiving a 5,000-fold excess of a minimally tumor-initiating TIC-dose. (A) Mixtures of 5610
5 TICs and
1610
6 human PBMCs were inoculated into NOD/SCID mice (N=3 for vehicle; N=5 for vehicle + PBMCs; N=4 for MT110 5 mg/kg; N=3 for MT110
50 mg/kg and N=3 for MT110 500 mg/kg group) and mice daily treated i.v. for 12 days with the indicated doses of MT110, or with vehicle controls in
the absence and presence of PBMCs. The mean tumor volume is given. P-value was determined by Student’s t-test. (B) Mixtures of 50,000 highly
tumorigenic HT-29 xenograft-derived CD44
high/CD24
high/EpCAM
high cells and 1610
5 human PBMCs were inoculated into 5 NOD/SCID mice per group
and mice daily treated i.v. for 12 days with the indicated doses of MT110, or with vehicle controls in the presence of PBMCs. The mean tumor volume
is given. P-value was determined by Student’s t-test. (C) Elimination of established tumors in NOD/SCID mice by treatment with MT110. Mixtures of
5610
6 TICs and 1610
7 human PBMCs were inoculated into 5 NOD/SCID mice per group to allow solid tumor formation. After tumor establishment at
day 4 mice were treated i.v. for 14 days with 2.5 mg/kg of MT110, or with vehicle control in presence of PBMCs. The mean tumor volume is given. P-
value was determined by Student’s t-test.
doi:10.1371/journal.pone.0013474.g004
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show that such mutated colorectal cancer cells are highly sensitive
to lysis by an EpCAM-specific T cell-engaging antibody,
suggesting that redirected lysis by T cells is not affected by
mutations in intracellular signaling proteins of the EGFR pathway.
This is explained by the mode of BiTE antibody action in which
the surface target antigen serves as mere anchor for T cell
engagement. The highly sub-saturating amounts of BiTE antibody
as used for redirected lysis are moreover unlikely to modulate
signaling activity of the target in a meaningful way. By contrast,
anti-receptor antibodies like panitumumab and cetuximab rely on
saturating target binding for signal inhibition.
Complete elimination of cancer-initiating cells by MT110-
engaged T cells was demonstrated in vitro by a highly sensitive
assay using soft agar colony growth, and in vivo in a xenograft mouse
model testing survival and tumor growth after inoculation of a high
TIC bolus. This high anti-tumor activity of MT110 will depend on
the expression of the target antigen EpCAM and equally hit
colorectal TICs and derived bulk tumor cells. Colorectal cancers
show the most frequent EpCAM expression of all human
adenocarcinoma analyzed to date [12] with 99.7% of primary
tumor samples (N=1,186 CRC patients) being positive. Moreover,
independent reports showed expression of EpCAM on colorectal
TICs [5,9,47,48], with evidence for a functional role of EpCAM in
tumorigenesis [5,20]. Involvement of EpCAM in wnt signaling [22]
may ensure that a majority of TICs need to express EpCAM for
proliferation and survival and that target loss may select a
population of tumor cells with reduced tumorigenic potential.
In our xenograft model, unstimulated human PBMCs were
mixed with TICs prior to subcutaneous implantation. In the
absence of BiTE antibody, this pre-mixing of cells will have no
biological consequence for T or tumor cells. Only when
intravenously infused BiTE antibody MT110 is reaching tumor
tissue in the skin, local T cells can become activated and eventually
lyse tumor cells. A recent study has shown that subcutaneous
tumors derived from a pancreas cancer cell line, which were
grown up to 300 mm
3 in the absence of human T cells, can be
eradicated by intraperitoneally administered human T cells in the
presence of intravenously administered BiTE antibody MT110
[49]. This suggests that BiTE antibodies do not necessarily rely on
tumor infiltrated T cells but can likewise engage peripheral T cells
for tumor rejection.
T cells may be particularly suited to eliminate disseminated
TICs. Effector memory T cells are constantly roaming our organs
in search for target cells, and are readily activated upon
rechallenge. Moreover, in colorectal cancer the presence of T
cells in tumors correlates with survival of patients [50]. We have
shown in clinical [40] and preclinical studies [51] that effector
memory T cells make the largest contribution to BiTE activity,
and that redirected T cells can lyse tumor cells independent of T
cell receptor specificity, MHC class I expression and the need for
costimulation [30,34,35]. By their search and destroy mode of
action and their high cytotoxic potential [30,31], T cells may be
able to find widely disseminated, temporarily non-proliferating
TICs. The elimination of therapy-resistant TICs or circulating
tumor cells by antibody-engaged T cells may improve the outcome
of standard therapies and reduce mortality of cancer patients.
Supporting Information
Materials and Methods S1 Supplementary Materials and
Methods.
Found at: doi:10.1371/journal.pone.0013474.s001 (0.03 MB
DOC)
Figure S1 Stem cell features of colorectal HT-29 cancer cells
trace with CD44
high/CD24
high/EpCAM
high phenotype. FACS
analysis of human HT-29 cells isolated from mouse xenografts
by (A) their levels of CD44 and CD24 expression, (B) expression of
human EpCAM, murine CD29 and CD45, viability using nuclear
dye propidium iodide, and (C) expression of ALDH by AldefluorH
staining in the presence or absence of ALDH inhibitor
diethylamino-benzaldehyde (DEAB). The x-axis shows mean
fluorescence intensity (MFI); the y-axis MFI for CD24 expression
(A), cell counts (B), or sideward scatter (C). (D) Sphere formation
and soft agar colony growth of CD44
high/CD24
high/EpCAM
high
and CD44
low/CD24
low/EpCAM
low HT-29 cancer cells. Spheres
and crystal violet-stained soft agar colonies were counted after 18
days. The mean number of spheres formed per 96-well plate is
shown +/- standard deviation (SD), as well as the mean number of
colony forming units (CFUs) +/- SD per cm2 from a triplicate
determination.
Found at: doi:10.1371/journal.pone.0013474.s002 (6.16 MB TIF)
Figure S2 Enhanced expression of cancer stem cell markers
in colorectal HT-29 CD44
high/CD24
high/EpCAM
high cells.
CD44
high/CD24
high/EpCAM
high and CD44
low/CD24
low/EpCAM
low
HT-29 cancer cells isolated from mouse xenograft have been
analyzed for EpCAM, B-catenin, ABCG2, CD44v6, CD133 and
CD166 by semiquantitative RT-PCR.
Found at: doi:10.1371/journal.pone.0013474.s003 (0.54 MB TIF)
Figure S3 Cytotoxicity assays using HT-29 xenograft-derived
and primary tumor-initiating target cells. (A) HT-29 xenograft-
derived bulk cells and cells sorted for CD44
high/CD24
high/
EpCAM
high and CD44
low/CD24
low/EpCAM
low were analyzed by
51Cr-release standard cytotoxicity assay. (B) TICs were analyzed by
51Cr-release standard cytotoxicity assay. CD8-enriched T cells were
used at an E:T ratio of 10:1. Results from triplicate determinations
are shown as mean values with standard deviations.
Found at: doi:10.1371/journal.pone.0013474.s004 (1.65 MB TIF)
Figure S4 Characterization of TICs for their cancer stem cell
phenotype. (A) Sphere formation (left panel) and FACS analysis of
cancer stem cells for markers by FACS analysis. MFI-values
relative to isotype control are shown (right panel). (B) TICs were
cultured under serum-free conditions in TIC medium or under
differentiation conditions in RPMI supplemented with 10% FCS
in collagen-coated culture flasks. Upper panel: FACS staining of
E-cadherin (black line) vs. control (grey line) and lower panel:
microphotographs of TICs cultured under FCS and TIC growth
conditions taken at 40x and 100x magnification. (C) TICs cultured
under serum-free conditions (TIC medium) and differentiation
conditions (RPMI supplemented with 10% FCS) analyzed for
PKH-26 staining by FACS after 48 and 96 h. (D) PKH-26 labeled
TICs were engrafted into NOD/SCID mice. After 4 weeks, the
retention of PKH-26 label was determined on TICs by FACS after
tumor digestion.
Found at: doi:10.1371/journal.pone.0013474.s005 (9.70 MB TIF)
Figure S5 Soft agar still supports colony growth after a long
time. Colony growth by TICs inoculated into 3- or 5-month old
soft agar.
Found at: doi:10.1371/journal.pone.0013474.s006 (2.11 MB TIF)
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